Sage Therapeutics reported a net income of $974.9 million for the fourth quarter of 2020, driven by $1.1 billion in net revenue, primarily from a collaboration with Biogen. The company ended the year with a strong cash position of $2.1 billion.
Entered into a global collaboration with Biogen worth up to $3.1 billion.
Reported positive interim data from Phase 3 open-label SHORELINE Study.
Ended 2020 with a cash balance of $2.1 billion.
Initiated six late-stage clinical trials in 2020, including four Phase 3 trials.
Sage anticipates cash, cash equivalents, restricted cash, and marketable securities of more than $1.7 billion at end of 2021 and does not anticipate receipt of any milestone payments from collaborations in 2021.
Analyze how earnings announcements historically affect stock price performance